RUI-products
Official Sponsor
More on Liquid GW1516
As many are aware GW1516 is one of the most exciting research chemicals currently available. We are proud to now be offering this compound for your research purposes. As always we will try to provide you with as much information possible to ensure the success of your research experiments.
The list of benefits attributed to this compound are quite impressive. It has been successfully used in research to improve such things as obesity, insulin resistance, metabolic syndrome, lipid profile (cholesterol), and cardiovascular disease as well as cardiovascular endurance. The studies referenced at the bottom of this article point out benefit after benefit in all of the above mentioned areas.
As with all research compounds there are direct and indirect side effects. The above mentioned things are all direct effects. GW is a peroxisome proliferator-activated receptor modulator (PRAR Modulator).There are small incidences documented in a very small number of studies with PRAR Modulators with one indirect effect that may be prudent to address. Apparently there is a small increase in the likelihood of research subjects developing stomach polyps. While this is worth being aware of, the good news is in those very same studies it is documented that administration of a COX-2 inhibitor virtually eliminates this increased possibility.
That's great news so what is a COX_2 Inhibitor? It is a type of NSAID, or NON Steroidal Anti Inflammatory Drug. A prescription example of a COX-2 Inhibitor would be the drug Celecoxib. The problem with the administration of a prescription COX-2 Inhibitor is they also contain traditional NSAID effects and should not be frequently administered to research subjects due to a myriad of potential adverse side effects. So what***8217;s so good about that news you may ask? Well there is another readily available, inexpensive COX-2 Inhibitor available OTC as a supplement. Tribulus terrestris is an effective COX-2 inhibitor that does not contain the additional forms of NSAIDS that would expose our research subjects to the previously mentioned potential adverse side effects.
To sum it up based on the information above and in the studies referenced below when researching with Liquid GW1516 the addition of the inexpensive supplement tribulus would probably be a prudent investment. Again we are very excited about offering the exceptional compound Liquid GW1516 for use in your research. We will continue to provide you with all the latest information to make your research as safe and successful as possible!
Refs:
*Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN
Department of Medicine, The Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6838, USA. PMID 14758356
*Berger J, Moller DE (2002). "The mechanisms of action of PPARs". Annu. Rev. Med. 53: 409***8211;35. doi:10.1146/annurev.med.53.082901.104018. PMID 11818483
* Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Salman Azhar Future Cardiol. 2010 September; 6(5): 657***8211;691. doi: 10.2217/fca.10.86 PMCID: PMC3246744 NIHMSID: NIHMS345357
* Evaluation of natural products on inhibition of inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) in cultured mouse macrophage cells. Hong CH, Hur SK, Oh OJ, Kim SS, Nam KA, Lee SK Department of Pharmacy, College of Pharmacy, Ewha Womans University, 11-1 Daehyun-dong, Seodaemun-ku, 120-750, Seoul, South Korea Journal of ethnopharmacology 83:1-2 2002 Nov pg 153-9 PMID 12413723
*Lipid effects of peroxisome proliferator-activated receptor-***948; agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of peroxisome pr... [Arterioscler Thromb Vasc Biol. 2012] - PubMed - NCBI
*Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model.Jahnke VE, Van Der Meulen JH, Johnston HK, Ghimbovschi S, Partridge T, Hoffman EP, Nagaraju K. Metabolic remodeling agents show beneficial ef... [Skelet Muscle. 2012] - PubMed - NCBI
As many are aware GW1516 is one of the most exciting research chemicals currently available. We are proud to now be offering this compound for your research purposes. As always we will try to provide you with as much information possible to ensure the success of your research experiments.
The list of benefits attributed to this compound are quite impressive. It has been successfully used in research to improve such things as obesity, insulin resistance, metabolic syndrome, lipid profile (cholesterol), and cardiovascular disease as well as cardiovascular endurance. The studies referenced at the bottom of this article point out benefit after benefit in all of the above mentioned areas.
As with all research compounds there are direct and indirect side effects. The above mentioned things are all direct effects. GW is a peroxisome proliferator-activated receptor modulator (PRAR Modulator).There are small incidences documented in a very small number of studies with PRAR Modulators with one indirect effect that may be prudent to address. Apparently there is a small increase in the likelihood of research subjects developing stomach polyps. While this is worth being aware of, the good news is in those very same studies it is documented that administration of a COX-2 inhibitor virtually eliminates this increased possibility.
That's great news so what is a COX_2 Inhibitor? It is a type of NSAID, or NON Steroidal Anti Inflammatory Drug. A prescription example of a COX-2 Inhibitor would be the drug Celecoxib. The problem with the administration of a prescription COX-2 Inhibitor is they also contain traditional NSAID effects and should not be frequently administered to research subjects due to a myriad of potential adverse side effects. So what***8217;s so good about that news you may ask? Well there is another readily available, inexpensive COX-2 Inhibitor available OTC as a supplement. Tribulus terrestris is an effective COX-2 inhibitor that does not contain the additional forms of NSAIDS that would expose our research subjects to the previously mentioned potential adverse side effects.
To sum it up based on the information above and in the studies referenced below when researching with Liquid GW1516 the addition of the inexpensive supplement tribulus would probably be a prudent investment. Again we are very excited about offering the exceptional compound Liquid GW1516 for use in your research. We will continue to provide you with all the latest information to make your research as safe and successful as possible!
Refs:
*Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN
Department of Medicine, The Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6838, USA. PMID 14758356
*Berger J, Moller DE (2002). "The mechanisms of action of PPARs". Annu. Rev. Med. 53: 409***8211;35. doi:10.1146/annurev.med.53.082901.104018. PMID 11818483
* Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Salman Azhar Future Cardiol. 2010 September; 6(5): 657***8211;691. doi: 10.2217/fca.10.86 PMCID: PMC3246744 NIHMSID: NIHMS345357
* Evaluation of natural products on inhibition of inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) in cultured mouse macrophage cells. Hong CH, Hur SK, Oh OJ, Kim SS, Nam KA, Lee SK Department of Pharmacy, College of Pharmacy, Ewha Womans University, 11-1 Daehyun-dong, Seodaemun-ku, 120-750, Seoul, South Korea Journal of ethnopharmacology 83:1-2 2002 Nov pg 153-9 PMID 12413723
*Lipid effects of peroxisome proliferator-activated receptor-***948; agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of peroxisome pr... [Arterioscler Thromb Vasc Biol. 2012] - PubMed - NCBI
*Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model.Jahnke VE, Van Der Meulen JH, Johnston HK, Ghimbovschi S, Partridge T, Hoffman EP, Nagaraju K. Metabolic remodeling agents show beneficial ef... [Skelet Muscle. 2012] - PubMed - NCBI
Last edited: